Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Telemedicine for Parkinson's Disease: Limited Engagement Between Local Clinicians and Remote Specialists.

Elson MJ, Stevenson EA, Feldman BA, Lim J, Beck CA, Beran DB, Schmidt PN, Biglan KM, Simone R, Willis AW, Dorsey ER, Boyd CM.

Telemed J E Health. 2018 Sep;24(9):722-724. doi: 10.1089/tmj.2017.0210. Epub 2018 Jan 3.

PMID:
29297769
2.

Preclinical motor manifestations of Huntington disease.

McGarry A, Biglan KM.

Handb Clin Neurol. 2017;144:93-98. doi: 10.1016/B978-0-12-801893-4.00007-9. Review.

PMID:
28947128
3.

Virtual visits for Parkinson disease: A multicenter noncontrolled cohort.

Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB.

Neurol Clin Pract. 2017 Aug;7(4):283-295. doi: 10.1212/CPJ.0000000000000371.

4.

National randomized controlled trial of virtual house calls for Parkinson disease.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W; Connect.Parkinson Investigators.

Neurology. 2017 Sep 12;89(11):1152-1161. doi: 10.1212/WNL.0000000000004357. Epub 2017 Aug 16.

5.

Patient and Physician Perceptions of Virtual Visits for Parkinson's Disease: A Qualitative Study.

Mammen JR, Elson MJ, Java JJ, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Dorsey ER.

Telemed J E Health. 2018 Apr;24(4):255-267. doi: 10.1089/tmj.2017.0119. Epub 2017 Aug 1.

PMID:
28787250
6.

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group STEADY‐PD III Investigators.

Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.

7.

The promise of telemedicine for chronic neurological disorders: the example of Parkinson's disease.

Schneider RB, Biglan KM.

Lancet Neurol. 2017 Jul;16(7):541-551. doi: 10.1016/S1474-4422(17)30167-9. Epub 2017 May 26. Review.

PMID:
28566190
8.

Palliative Care in Huntington Disease: Personal Reflections and a Review of the Literature.

Tarolli CG, Chesire AM, Biglan KM.

Tremor Other Hyperkinet Mov (N Y). 2017 Apr 11;7:454. doi: 10.7916/D88057C7. eCollection 2017. Review.

9.

Moving Parkinson care to the home.

Dorsey ER, Vlaanderen FP, Engelen LJ, Kieburtz K, Zhu W, Biglan KM, Faber MJ, Bloem BR.

Mov Disord. 2016 Sep;31(9):1258-62. doi: 10.1002/mds.26744. Epub 2016 Aug 8. Review.

10.

Wearable Sensors in Huntington Disease: A Pilot Study.

Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, Cai H, Reilmann R, Little MA, Gwin JT, Biglan KM, Dorsey ER.

J Huntingtons Dis. 2016 Jun 18;5(2):199-206. doi: 10.3233/JHD-160197.

PMID:
27341134
11.

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.

Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W.

Telemed J E Health. 2016 Jul;22(7):590-8. doi: 10.1089/tmj.2015.0191. Epub 2016 Feb 17.

12.

Erratum To: Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.

Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER.

Trials. 2016 Jan 5;17:7. doi: 10.1186/s13063-015-0984-7. No abstract available.

13.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
14.

Feasibility of Virtual Research Visits in Fox Trial Finder.

Dorsey ER, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdhury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, Biemiller RA, Biglan KM.

J Parkinsons Dis. 2015;5(3):505-15. doi: 10.3233/JPD-150549.

15.

Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study.

Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, Dorsey ER, Little MA.

Parkinsonism Relat Disord. 2015 Jun;21(6):650-3. doi: 10.1016/j.parkreldis.2015.02.026. Epub 2015 Mar 7.

PMID:
25819808
16.

Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial.

Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, Dorsey ER.

Trials. 2014 Nov 27;15:465. doi: 10.1186/1745-6215-15-465. Erratum in: Trials. 2016;17:7.

17.

A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders.

Abdolahi A, Bull MT, Darwin KC, Venkataraman V, Grana MJ, Dorsey ER, Biglan KM.

Health Informatics J. 2016 Jun;22(2):304-11. doi: 10.1177/1460458214556373. Epub 2014 Nov 11.

PMID:
25391849
18.

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

Killoran A, Biglan KM.

Mov Disord. 2014 Sep 15;29(11):1404-13. doi: 10.1002/mds.26014. Epub 2014 Aug 27. Review.

PMID:
25164707
19.

A pilot study of virtual visits in Huntington disease.

Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, Dorsey ER, Biglan KM.

J Huntingtons Dis. 2014;3(2):189-95. doi: 10.3233/JHD-140102.

PMID:
25062861
20.

The past, present, and future of telemedicine for Parkinson's disease.

Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Dorsey ER, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR; International Parkinson and Movement Disorder Society Telemedicine Task Force.

Mov Disord. 2014 Jun;29(7):871-83. doi: 10.1002/mds.25903. Epub 2014 May 17. Review.

PMID:
24838316
21.

Virtual visits for Parkinson disease: A case series.

Venkataraman V, Donohue SJ, Biglan KM, Wicks P, Dorsey ER.

Neurol Clin Pract. 2014 Apr;4(2):146-152.

22.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

23.

Natural history of Huntington disease.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators.

JAMA Neurol. 2013 Dec;70(12):1520-30. doi: 10.1001/jamaneurol.2013.4408.

PMID:
24126537
24.

Telemedicine in Leading US Neurology Departments.

George BP, Scoglio NJ, Reminick JI, Rajan B, Beck CA, Seidmann A, Biglan KM, Dorsey ER.

Neurohospitalist. 2012 Oct;2(4):123-8. doi: 10.1177/1941874412450716.

25.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

26.

Refining the diagnosis of Huntington disease: the PREDICT-HD study.

Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Front Aging Neurosci. 2013 Apr 2;5:12. doi: 10.3389/fnagi.2013.00012. eCollection 2013.

27.

Randomized controlled clinical trial of "virtual house calls" for Parkinson disease.

Dorsey ER, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, Beck CA, Rajan B, Seidmann A, Biglan KM.

JAMA Neurol. 2013 May;70(5):565-70. doi: 10.1001/jamaneurol.2013.123.

28.

Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study.

Dorsey ER, Brocht AF, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I.

J Huntingtons Dis. 2013;2(4):509-15. doi: 10.3233/JHD-130071.

PMID:
25062735
29.

8-OHdG: its (limited) potential as a biomarker for Huntington's disease.

Killoran A, Biglan KM.

Biomark Med. 2012 Dec;6(6):777-80. doi: 10.2217/bmm.12.84. No abstract available.

PMID:
23227841
30.

Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely.

Abdolahi A, Scoglio N, Killoran A, Dorsey ER, Biglan KM.

Parkinsonism Relat Disord. 2013 Feb;19(2):218-21. doi: 10.1016/j.parkreldis.2012.10.008. Epub 2012 Oct 25.

31.

Web-based clinical assessments for Parkinson's disease: reliable and feasible.

Grana MJ, Bull MT, Venkataraman V, Dorsey ER, Biglan KM.

Mov Disord. 2012 Sep 15;27(11):1466. doi: 10.1002/mds.25121. Epub 2012 Sep 18. No abstract available.

PMID:
22991090
32.

Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease.

Unschuld PG, Joel SE, Liu X, Shanahan M, Margolis RL, Biglan KM, Bassett SS, Schretlen DJ, Redgrave GW, van Zijl PC, Pekar JJ, Ross CA.

Neurosci Lett. 2012 Apr 18;514(2):204-9. doi: 10.1016/j.neulet.2012.02.095. Epub 2012 Mar 7.

33.

Therapeutics in Huntington's Disease.

Killoran A, Biglan KM.

Curr Treat Options Neurol. 2012 Feb 8. [Epub ahead of print]

PMID:
22314929
34.

Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, Kieburtz K; Huntington Study Group Pre-2CARE Investigators.

J Huntingtons Dis. 2012;1(1):65-9. doi: 10.3233/JHD-2012-120007.

35.

Group patient visits for Parkinson disease: a randomized feasibility trial.

Dorsey ER, Deuel LM, Beck CA, Gardiner IF, Scoglio NJ, Scott JC, Marshall FJ, Biglan KM.

Neurology. 2011 May 3;76(18):1542-7. doi: 10.1212/WNL.0b013e3182194bad. Epub 2011 Apr 27.

36.

Tapping in Huntington disease: a path forward to preventive therapies?

Biglan KM.

Neurology. 2010 Dec 14;75(24):2142-3. doi: 10.1212/WNL.0b013e318203f0cd. Epub 2010 Nov 10. No abstract available.

PMID:
21068428
37.

Neurocognitive signs in prodromal Huntington disease.

Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH.

Neuropsychology. 2011 Jan;25(1):1-14. doi: 10.1037/a0020937.

38.

A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups.

Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM.

Mov Disord. 2010 Oct 15;25(13):2128-35. doi: 10.1002/mds.23160.

PMID:
20824736
39.

Reply: An exploration of the burden experienced by spousal caregivers of individuals with Parkinson's disease.

Deuel LM, Chesire AM, Eason S, Como PG, Biglan KM.

Mov Disord. 2010 Oct 15;25(13):2254-5. doi: 10.1002/mds.23273. No abstract available.

PMID:
20803516
40.

Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease.

Dorsey ER, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, Miller D, Reminick JI, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Biglan KM.

Mov Disord. 2010 Aug 15;25(11):1652-9. doi: 10.1002/mds.23145.

PMID:
20533449
41.

Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.

Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

Arch Neurol. 2009 Sep;66(9):1099-104. doi: 10.1001/archneurol.2009.159. Epub 2009 Jul 13.

42.

Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study.

Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, Carlozzi NE, Duff K, Beglinger LJ, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group.

Mov Disord. 2009 Sep 15;24(12):1763-72. doi: 10.1002/mds.22601.

43.

Telemedicine for the care of nursing home residents with Parkinson's disease.

Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Dorsey ER.

Mov Disord. 2009 May 15;24(7):1073-6. doi: 10.1002/mds.22498.

PMID:
19353687
44.

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.

Biglan KM, Holloway RG Jr, McDermott MP, Richard IH; Parkinson Study Group CALM-PD Investigators.

Neurology. 2007 Jul 10;69(2):187-95.

PMID:
17620552
45.

Neuroprotection in Parkinson's disease: an elusive goal.

Biglan KM, Ravina B.

Semin Neurol. 2007 Apr;27(2):106-12. Review.

PMID:
17390255
46.

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM.

Neurology. 2007 Jan 30;68(5):384-6. Epub 2006 Nov 2.

PMID:
17082464
47.

The eyes as a window into disease prevention.

Biglan KM, Halmagyi M.

Neurology. 2006 Aug 8;67(3):376-7. No abstract available.

PMID:
16894093
48.

Rasagiline improves quality of life in patients with early Parkinson's disease.

Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I; Parkinson Study Group.

Mov Disord. 2006 May;21(5):616-23.

PMID:
16450340
49.

Surrogate endpoints in Parkinson's disease research.

Biglan KM, Holloway RG.

Curr Neurol Neurosci Rep. 2003 Jul;3(4):314-20. Review.

PMID:
12930701
50.

Restless legs syndrome and drug-induced akathisia in headache patients.

Young WB, Piovesan EJ, Biglan KM.

CNS Spectr. 2003 Jun;8(6):450-6.

PMID:
12858135

Supplemental Content

Loading ...
Support Center